Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease | Scientific Reports
Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease | Scientific Reports
Antibodies gone bad – the molecular mechanism of light chain amyloidosis - Absmeier - 2023 - The FEBS Journal - Wiley Online Library
Medicina | Free Full-Text | The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
Guide to Antibody structure and isotypes | Abcam
Biomedicines | Free Full-Text | Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
Validation of serum free light chain reference ranges in primary care - Luca Galvani, Jane Flanagan, Mansour Sargazi, William D Neithercut, 2016
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
Frontiers | Understanding AL amyloidosis with a little help from in vivo models
IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases
Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust
SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain
Immunoglobulin Light Chain - an overview | ScienceDirect Topics